ASX · BIT.AX
Biotron Limited
A$0.00+A$0.00 (0.0%)
Biotron Limited’s quoted price sits in the lower half of its reported 52-week range, 60.0% below the high.
Loading market information…
OTC · TSOI · USD
Stock price, earnings
Quote as of Oct 28, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Therapeutic Solutions International, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Therapeutic Solutions International, Inc. is dedicated to modulating the immune system to address a diverse array of serious conditions. The company formulates immune-modulatory agents targeting cancers, schizophrenia, suicidal ideation, and various neurological disorders like traumatic brain injury and chronic traumatic encephalopathy, alongside lung pathologies and general health maintenance. Its premier product, QuadraMune, is a patented, synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquionone, engineered to amplify natural killer cell activity and foster healthy cytokine production. In addition to QuadraMune, the company provides a range of nutraceuticals. These include ProJuvenol, an anti-aging capsule blend; various pterostilbene formulations like NanoStilbene (a nanoemulsion), DermalStilbene (a topical spray), IsoStilbene (an injectable form), and NeuroStilbene (an intranasal version); Nano Cannabidiol, a nanoparticle cannabidiol, and its composite NanoPlus (with NanoStilbene); as well as specialized blends such as NanoPSA (combining NanoStilbene and broccoli sprout extract) and the NLRP3 Trifecta (a two-product system with NanoPSA and GTE-50 green tea extract). Furthermore, the company is actively developing advanced therapeutics for chronic traumatic encephalopathy, traumatic brain injury, and lung diseases. Founded in 2007, Therapeutic Solutions International, Inc. is headquartered in Elk City, Idaho.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:17 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$0.00+A$0.00 (0.0%)
Biotron Limited’s quoted price sits in the lower half of its reported 52-week range, 60.0% below the high.
€0.03-€0.00 (-1.47%)
Biophytis S.A.’s quoted price sits in the lower half of its reported 52-week range, 79.12% below the high.
$0.00$0.00 (0.0%)
Global Roundtable Corporation’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$0.00$0.00 (0.0%)
RespireRx Pharmaceuticals Inc.’s quoted price sits in the upper half of its reported 52-week range, 33.33% below the high.
$0.06$0.00 (0.0%)
SYBLEU Inc’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.02$0.00 (0.0%)
Mednow Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Pathfinder Cell Therapy, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
MultiCell Technologies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.0% below the high.
